Rapid determination of telmisartan in human plasma by HPLC using a monolithic column with fluorescence detection and its application to a bioequivalence study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 29, 2009, Pages 3729-3733

  Zhang, He ^a,b,c   Jiang, Yunyun ^a,b,c   Wen, Jun ^a,b,c   Zhou, Tingting ^a,b,c   Fan, Guorong ^a,b,c   Wu, Yutian ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI KEY LABORATORY FOR PHARMACEUTICAL METABOLITE RESEARCH   (China)

^c Shanghai Research Centre for Drug Chinese Materia Medica Metabolism   (China)

Author keywords

Bioequivalence; Fluorescence detection; HPLC; Monolithic column; Plasma; Telmisartan

Indexed keywords

BIOEQUIVALENCE STUDY; CALIBRATION CURVES; EMISSION WAVELENGTH; EXCITATION WAVELENGTH; FLUORESCENCE DETECTION; HIGH THROUGHPUT; HPLC METHOD; HUMAN PLASMAS; MONOLITHIC COLUMNS; NAPROXENS; PROTEIN PRECIPITATION; RAPID DETERMINATION; SAMPLE PREPARATION; TELMISARTAN;

ACETONITRILE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PLASMA (HUMAN); PLASMAS;

POLYMORPHISM;

NAPROXEN; TELMISARTAN;

ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL; TABLET FORMULATION; VALIDATION STUDY;

BENZIMIDAZOLES; BENZOATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE; THERAPEUTIC EQUIVALENCY;

EID: 72049110475     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.08.028     Document Type: Article

References (25)

1. Pitt B., and Konstam M.A. Am. J. Cardiol. 82 (1998) 47S Supplement 1
2. Willenheimer R., Dahlof B., Rydberg E., and Erhardt L. Eur. Heart J. 20 (1999) 997
3. Unger T. Am. J. Cardiol. 84 10 (1999) 9S Supplement 1
4. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., and Snapinn S. Lancet 359 (2002) 1004
5. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., and Wedel H. Lancet 359 (2002) 995
6. Young J.B., Dunlap M.E., Pfeffer M.A., Probstfield J.L., Cohen-Solal A., Dietz R., Granger C.B., Hradec J., Kuch J., McKelvie R.S., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Held P., Solomon S.D., Yusuf S., and Swedberg K. Circulation 110 (2004) 2618
7. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., and Anderson C. N. Engl. J. Med. 358 (2008) 1547
8. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Circulation 109 (2004) 2054
9. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Hypertension 43 (2004) 993
10. Christel H., Liane G.-S., Ulrich K., and Uwe K. Anal. Chim. Acta 560 (2006) 35
11. Xu M., Song J., and Liang Y. J. Pharm. Biomed. Anal. 34 (2004) 681
12. Stangier J., Schmid J., Turck D., Switek H., Verhagen A., Peeters P.A., van Marle S.P., Tamminga W.J., Sollie F.A., and Jonkman J.H. J. Clin. Pharmacol. 40 (2000) 1312
13. Torrealday N., Gonzalez L., Alonso R.M., Jimenez R.M., and Ortiz Lastra E. J. Pharm. Biomed. Anal. 32 (2003) 847
14. Tian X., Jia L., Qiao H., Zhang L., Guo Y., Gao N., and Zhang Q. Chin. Hosp. Pharm. J. 25 (2005) 318
15. Zhou Y., Li X., Shi Q., Lan C., Jiang W., and Chen L. Chin. Pharm. J. 40 (2005) 377
16. Shen J., Jiao Z., Li Z., Shi X., and Zhong M. Pharmazie 60 (2005) 418
17. Nie J., Zhang M., Fan Y., Wen Y., Xiang B., and Feng Y. J. Chromatogr. B 828 (2005) 62
18. Christel H., Liane G.-S., Ulrich K., and Uwe K. Anal. Chim. Acta 560 (2006) 41
19. Li P., Wang Y., Wang Y., Tang Y., Paul Fawcett J., Cui Y., and Gua J. J. Chromatogr. B 828 (2005) 126
20. Chen B., Liang Y., Wang Y., Deng F., Zhou P., u Guo F., and Huang L. Anal. Chim. Acta 540 (2005) 367
21. Zhang P., Zhang Y., Chen X., Li R., Yin J., and Zhong D. Arzneimittelforschung 56 (2006) 569
22. FDA Guidance for Industry, Biaoavaliability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), 2000, (website: http://www.fda.gov/cder/guidance/index.htm).
23. ICH Harmonised tripartite guideline validation of analytical procedures: text and methodology Q2 (R1), Parent Guideline dated October 27, 1994 (complementary guideline on methodology dated November 6, 1996 incorporated in November 2005), website: http://www.ich.org/LOB/media/MEDIA417.pdf.
24. United States Pharmacopeia, 28th ed., United States Pharmacopeial Convention, Rockville, 2005, pp. 2748-2751.
25. FDA Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001 (website: http://www.fda.gov/cder/guidance/index.htm).